Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis
- 21 Downloads
Despite the major improvement in therapeutic management of thalassemia major, iron overload is considered a challenging conundrum in these patients and heart disease still remains a major cause of morbidity and mortality in these patients. Therefore, this study aimed to investigate the prevalence of cardiac iron overload and cardiovascular complications in transfusion-dependent thalassemia patients in the worldwide. The following databases were searched: ISI/Web of Science, Embase, PubMed, Scopus, up to February 30, 2018. The quality of the studies was evaluated using the Joanna Briggs Institute Prevalence Critical Appraisal Tool. The random model based on Metaprop was used. One hundred forty-two studies were included. The total number of patients included was 26,893. The mean age of patients was 22.6 (SD = 1.7) years. Based on Metaprop, the overall prevalence of cardiac iron overload/myocardial sidoresis (T2* < 20 ms) and cardiac complications in thalassemia major patients in the worldwide was 25% (95% CI 22–28%) and 42% (95% CI 37–46%), respectively. The results of this study show that the prevalence of cardiac iron overload and cardiovascular complications in patients with thalassemia major is almost high. Therefore, iron chelation and careful monitoring of serum ferritin level will prevent the cardiac iron overload, and interval monitoring of patients with transfusion-dependent thalassemia (TDT) by echocardiography and electrocardiography will help with early detection of cardiovascular complications.
KeywordsCardiac iron overload Myocardial sidoresis Cardiac complications Major thalassemia
Cardiac iron overload
F. Koohi was the main investigator and drafted the manuscript. E. Miri-Moghaddam and T. Kazemi were the study supervisors and contributed to all aspects of the study.
This study is financially supported by the Research Deputy of Birjand University of Medical Sciences.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J (2013) Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 128:281–308CrossRefGoogle Scholar
- 5.Krittayaphong R, Viprakasit V, Saiviroonporn P, Siritanaratkul N, Siripornpitak S, Meekaewkunchorn A, Kirawittaya T, Sripornsawan P, Jetsrisuparb A, Srinakarin J, Wong P, Phalakornkul N, Sinlapamongkolkul P, Wood J (2017) Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: a multicenter study based on real-world data. Blood Cell Mol Dis 66:24–30CrossRefGoogle Scholar
- 7.Bonifazi F, Conte R, Baiardi P, Bonifazi D, Felisi M, Giordano P, Giannuzzi V, Iacono A, Padula R, Pepe A, Caterina Putti M, Ruggieri L, Carlo del Vecchio G, Filosa A, Maggio A, Ceci A, HTA-THAL Multiregional Registry (2017) Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin 33:1525–1533CrossRefGoogle Scholar
- 9.Patel HV, Qari M, Mousa SA et al (2012) Iron balance in β-thalassemia: maintaining an antioxidant/oxidant ratio. J Appl Hematol 3:4Google Scholar
- 17.Deeks JJ, Higgins JP, Altman DG (2008) Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions: Cochrane book series 26:243–296Google Scholar
- 24.Richardson M, Matthews R, Alison J et al (1993) Prevention of heart disease by subcutaneous desferoxamine in patients with thalassaemia major. Intern Med J 23:656–661Google Scholar
- 25.Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489–496Google Scholar
- 27.Yaghobi M, Miri-Moghaddam E, Majid N et al (2017) Complications of transfusion-dependent β-thalassemia patients in Sistan and Baluchistan, south-east of Iran. Int J Hematol Oncol Stem Cell Res 11:268Google Scholar
- 30.Aydinok Y, Porter JB, Piga A, Elalfy M, el-Beshlawy A, Kilinç Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ (2015) Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. Eur J Haematol 95:244–253CrossRefGoogle Scholar
- 36.Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassarà F, Harmatz P, Wood J, Gluud C (2011) Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cell Mol Dis 47:166–175CrossRefGoogle Scholar